South Korea Dopamine Agonist Market Size, Share, and COVID-19 Impact Analysis, By Drug (Non-ergot Dopamine Agonists and Ergot Alkaloids), By Route of Administration (Oral and Injectable), By Application (Parkinson’s Disease and Restless Legs Syndrome (RLS)), and South Korea Dopamine Agonist Market Insights, Industry Trend, Forecasts to 2035

  South Korea Dopamine Agonist Market Size Insights Forecasts to 2035

• The South Korea Dopamine Agonist Market Size Was Estimated at USD 30.8 Million in 2024
• The Market Size is Expected to Grow at a CAGR of around 6.44% from 2025 to 2035
• The South Korea Dopamine Agonist Market Size is Expected to Reach USD 61.2 Million by 2035

According to a research report published by Spherical Insights & Consulting, the South Korea Dopamine Agonist Market Size is anticipated to reach USD 61.2 million by 2035, growing at a CAGR of 6.44% from 2025 to 2035. The growing incidence of Parkinson's disease, restless legs syndrome, and other neurological conditions that call for dopamine-modulating therapies is the main driver of the market. The occurrence of these disorders is predicted to rise as the reginal population ages, which will increase demand even further.

Market Overview

The market for drugs that activate dopamine receptors in the brain to replicate the effects of dopamine is known as the "dopamine agonist market." The main problems that these agonists are used to treat include hyperprolactinemia and movement disorders like Parkinson's disease. Both ergot-derived and non-ergot-derived dopamine agonists are available on the market, and they differ in their distribution and administration methods. Parkinson's disease motor symptoms, such as tremors, stiffness, and slow movement, are treated with dopamine agonists. Non-motor symptoms like mood swings and sleep issues can also be helped by them. One significant contributing factor is the aging population, which raises the prevalence of Parkinson's disease and restless legs syndrome, both of which can be successfully treated with dopamine agonists. The goal of ongoing research and development is to produce dopamine agonists that are more potent and have fewer adverse effects. Research on the causes, prevention, and treatment of neurological conditions like Parkinson's disease that depend on dopamine agonists is frequently funded by governments. Clinical trials for novel dopamine agonists or for examining novel applications for already-approved ones may be funded by governments.

Report Coverage

This research report categorizes the market for South Korea dopamine agonist market based on various segments and regions forecasts revenue growth, and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the South Korea dopamine agonist market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment South Korea dopamine agonist market.

Driving Factors        

The rising prevalence of Parkinson’s disease and restless legs syndrome, increasing geriatric population, and growing awareness of neurological disorders. Advances in drug delivery systems and the development of long-acting formulations enhance treatment efficacy and patient compliance. Additionally, increased healthcare spending, favorable reimbursement policies, and ongoing R&D activities by pharmaceutical companies contribute to market growth.

Restraining Factors

The high cost of treatment and limited access to advanced healthcare in low-income regions. Adverse effects such as impulse control disorders, hallucinations, and sleep disturbances reduce patient compliance and hinder adoption. The availability of alternative therapies and the complexity of accurate diagnosis also challenge market growth.

Market Segmentation

The South Korea dopamine agonist market share is classified into drug, route of administration, and application.

• The non-ergot dopamine agonists segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The South Korea dopamine agonist market is segmented by drug into non-ergot dopamine agonists and ergot alkaloids. Among these, the non-ergot dopamine agonists segment held a significant share in 2024 and is expected to grow at a substantial CAGR during the forecast period. The superior safety profile, less likelihood of fibrosis-related adverse effects, and high effectiveness in treating neurological conditions including Parkinson's disease and restless legs syndrome (RLS) are the reasons for their dominance. Because they are more tolerable and cause fewer cardiovascular side effects than their ergot-derived counterparts, non-ergot dopamine agonists, including pramipexole, ropinirole, rotigotine, and apomorphine have become widely used.

• The oral segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The South Korea dopamine agonist market is segmented by route of administration into oral and injectable. Among these, the oral segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period. The large market share is a result of oral formulations like as pramipexole, ropinirole, and bromocriptine being the first-line treatment for ailments like Parkinson's disease and restless legs syndrome (RLS).

• The parkinson's disease segment dominated the share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The South Korea dopamine agonist market is segmented by application into parkinson's disease and restless legs syndrome (RLS). Among these, the parkinson's disease segment dominated the share in 2024 and is expected to grow at a significant CAGR during the forecast period. Broad availability, ease of use, and high rates of prescription refills for long-term illnesses, including RLS and Parkinson's disease. Retail pharmacies offer reasonable cost, insurance coverage, and easy access to oral dopamine agonists, patients choose them.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the South Korea dopamine agonist market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborate analysis focusing on the companies' current news and developments, including product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Daewoong Pharmaceutical
• Celltrion
• Samsung Biologics
• Yuhan Corporation
• Chong Kun Dang
• Hanmi Pharmaceutical
• Hutecs Korea Pharmaceutical Co. Ltd.
• Icure Pharmaceutical Inc
• Ildong Pharmaceutical Co Ltd
• Ilyang Pharmaceutical Co Ltd
• Korea Pharma Co Ltd
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at South Korea, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the South Korea dopamine agonist market based on the below-mentioned segments:

South Korea Dopamine Agonist Market, By Drug

• Non-ergot Dopamine Agonists
• Ergot Alkaloids

South Korea Dopamine Agonist Market, By Route Of Administration

• Oral
• Injectable

South Korea Dopamine Agonist Market, Application

• Parkinson's Disease
• Restless Legs Syndrome (RLS)